Breaking Advances
Cancer Res March 15 2014 74 (6) 1623-1624;
This study describes the first universal and specific marker to detect circulating sarcoma cells in the blood, with the capability to detect any type of sarcoma, offering a key prognostic tool to monitor cancer metastasis and relapse in sarcoma patients.
A long noncoding RNA known to be oncogenic is found to promote cell death during genotoxic stress, suggesting a novel clinical correlation between this little-understood class of RNAs and genotoxic cancer therapies.
Understanding how limits on cellular replication influence the fate of altered but nonneoplastic cells in healthy tissue may make it possible to estimate the risk posed by cancer-associated mutations found in healthy individuals.
This paper utilizes a new method to identify immune components critical to the efficacy of antitumor immune responses to tumors.
A transcription factor that functions in tumor suppression was unexpectedly found to instead promote renal tumor growth under conditions of PI3K–AKT inhibition, with implications on how to improve antitumor responses.
These results show that circulating colon tumor cells are genetically different from the primary colon tumor, exhibiting an immunosuppressive phenotype that enables them to evade immune eradication.
These findings show how coordinated regulation of gene expression programs by two distinct epigenetic modifiers drives malignant properties in breast cancer cells.
These studies show that changes in the peripheral nervous system occur early during tumor development and may play an important role in disease progression.
This study of a histone deacetylase that is essential for mitogenic signaling in liver cancers may offer a new interventional target for more effective therapy.
These findings reveal an unexpected function of the tumor suppressor p16INK4A in promoting the homologous recombination pathway of DNA repair, suggesting that p16INK4A status in head and neck cancer patients may offer an independent marker to predict their response to radiotherapy.
This study presents a novel candidate prognostic and therapeutic target in aggressive brain cancers, with implications for understanding the basis for poor patient survival.
These findings offer a rationale for the therapeutic exploration of treatments inducing ER stress against mutant ERBB2-expressing breast tumor cells.
These findings link a TRIM family protein that binds DNA and p53 to radioresistance in pancreatic cancer, suggesting its candidacy as a therapeutic target to improve the efficacy of DNA-damaging treatments used to treat this disease.
These findings offer a preclinical proof of concept that IL-33 improves the immune potency of tumor vaccines, promoting tumor cell clearance and regressions to fully empower cancer immunotherapy.
These findings offer a preclinical rationale to explore delivery of a tumor-suppressive microRNA as an effective therapeutic strategy to eradicate multiple myeloma cells.
These results show how regional aberrations in chromosome copy number can lead to loss of multiple important tumor-suppressor functions in cancer.
This study of distinct subsets of adult tissue progenitors points to a maturation arrest of oligodendroglial precursor cells in the pathogenesis of PDGF-dependent brain tumors.
These findings define an immunotherapeutic target for treatment of a form of brain malignancy, which acts by depleting cancer stem-like cells required to sustain the malignancy in a mouse model system.
These findings define opposing functions of the two isoforms of the SYK kinase in liver cancer, with the larger isoform enhancing invasion and the smaller isoform enhancing metastasis, patterns that in patient specimens offer strong predictors of overall survival.
Using cancer stem-like cells isolated directly from metastatic colorectal patients, this study reveals the importance of both EGFR and MET signaling and offers a strong preclinical proof of concept for concurrent targeting of both of these receptors in the clinical setting.
This article identifies a key determinant in degradation of the androgen receptor, highlighting its importance as a candidate therapeutic target in managing prostate cancers marked by loss of the tumor suppressor PTEN.